NCT04935099

Brief Summary

This study aims to investigate whether consuming a drink containing powdered blueberries (equivalent to 150 g fresh fruit) can improve mood and cognition in healthy young adults. Blood biomarkers of inflammation and neurotransmitter turnover will be analyzed as well as responses to computer-based cognitive tasks designed to measure verbal memory, executive function, and emotional processing.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
33

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started May 2021

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 26, 2021

Completed
1 day until next milestone

First Submitted

Initial submission to the registry

May 27, 2021

Completed
26 days until next milestone

First Posted

Study publicly available on registry

June 22, 2021

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 27, 2021

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 27, 2021

Completed
Last Updated

September 21, 2021

Status Verified

September 1, 2021

Enrollment Period

3 months

First QC Date

May 27, 2021

Last Update Submit

September 20, 2021

Conditions

Keywords

blueberryanthocyaninsflavonoids

Outcome Measures

Primary Outcomes (10)

  • Global transient mood as measured by PANAS-X

    The Positive and Negative Affect Schedule - Expanded Form (PANAS-X) is a validated, self-rated measure of affective state, encompassing two general dimensions (positive and negative affect). These will be calculated separately by adding the values of the individual items (21 positive and 25 negative items). Thus, the scales will range from 0 to 84 points for positive affect and from 0 to 100 for negative affect, with a higher score indicating greater positive or negative affect. Positive affect will be considered the primary measure.

    baseline

  • Global transient mood as measured by PANAS-X

    The Positive and Negative Affect Schedule - Expanded Form (PANAS-X) is a validated, self-rated measure of affective state, encompassing two general dimensions (positive and negative affect). These will be calculated separately by adding the values of the individual items (21 positive and 25 negative items). Thus, the scales will range from 0 to 84 points for positive affect and from 0 to 100 for negative affect, with a higher score indicating greater positive or negative affect. Positive affect will be considered the primary measure

    2 hours post-ingestion

  • Negative interpretation bias

    A negative interpretation bias is defined as a tendency to interpret ambiguous information in a consistently threatening or negative manner, thus serving as an objective indicator of affective state. In this task, participants will be asked to categorize facial expressions of anger, happiness, and surprise as either positive or negative. Interpretation bias will be operationalized as the percent of trials in which surprised faces were rated as negative, out of the total number of surprise trials (48 trials).

    baseline

  • Negative interpretation bias

    A negative interpretation bias is defined as a tendency to interpret ambiguous information in a consistently threatening or negative manner, thus serving as an objective indicator of affective state. In this task, participants will be asked to categorize facial expressions of anger, happiness, and surprise as either positive or negative. Interpretation bias will be operationalized as the percent of trials in which surprised faces were rated as negative, out of the total number of surprise trials (48 trials).

    2 hours post-ingestion

  • Cognitive flexibility (accuracy on post-switch trials)

    A task-switching test will be used to assess cognitive performance when switching between two predictable tasks requiring simple numerical decisions. The main outcome of interest is the average accuracy of responses to post-switch trials (those immediately following a switch to a new task).

    baseline

  • Cognitive flexibility (accuracy on post-switch trials)

    A task-switching test will be used to assess cognitive performance when switching between two predictable tasks requiring simple numerical decisions. The main outcome of interest is the average accuracy of responses to post-switch trials (those immediately following a switch to a new task).

    2 hours post-ingestion

  • Delayed verbal memory on RAVLT

    The Rey Auditory Verbal Learning Test (RAVLT) is a standard neuropsychological assessment designed to evaluate verbal memory. The participant hears a list of 15 words and is asked to recall as many words as possible. This procedure is repeated five times. The main outcome of interest is the number of correctly recalled words 20 minutes after the last presentation of the list of words (Trial A7).

    baseline

  • Delayed verbal memory on RAVLT

    The Rey Auditory Verbal Learning Test (RAVLT) is a standard neuropsychological assessment designed to evaluate verbal memory. The participant hears a list of 15 words and is asked to recall as many words as possible. This procedure is repeated five times. The main outcome of interest is the number of correctly recalled words 20 minutes after the last presentation of the list of words (Trial A7).

    2 hours post-ingestion

  • Serum brain-derived neurotrophic factor (BDNF)

    Serum levels of BDNF will be analyzed using enzyme-linked immunosorbent assay (ELISA).

    baseline

  • Serum brain-derived neurotrophic factor (BDNF)

    Serum levels of BDNF will be analyzed using enzyme-linked immunosorbent assay (ELISA).

    2 hours post-ingestion

Secondary Outcomes (34)

  • Distinct affective states as measured by PANAS-X subscales

    baseline

  • Distinct affective states as measured by PANAS-X subscales

    2 hours post-ingestion

  • Reaction time to positive stimuli

    baseline

  • Reaction time to positive stimuli

    2 hours post-ingestion

  • Reaction time to negative stimuli

    baseline

  • +29 more secondary outcomes

Other Outcomes (2)

  • Recognition memory on RAVLT

    baseline

  • Recognition memory on RAVLT

    2 hours post-ingestion

Study Arms (2)

Blueberry/Placebo

EXPERIMENTAL

In this arm, participants will receive the blueberry intervention first, followed by the placebo one week later.

Dietary Supplement: Wild blueberry powderDietary Supplement: Placebo powder

Placebo/Blueberry

EXPERIMENTAL

In this arm, participants will receive the placebo first, followed by the blueberry intervention one week later.

Dietary Supplement: Wild blueberry powderDietary Supplement: Placebo powder

Interventions

Wild blueberry powderDIETARY_SUPPLEMENT

22 g freeze-dried wild blueberry (Vaccinium angustifolium) powder, mixed with 250 ml water, and served in an opaque container.

Blueberry/PlaceboPlacebo/Blueberry
Placebo powderDIETARY_SUPPLEMENT

22 g placebo powder matched for macronutrients and flavor, mixed with 250 ml water, and served in an opaque container.

Blueberry/PlaceboPlacebo/Blueberry

Eligibility Criteria

Age18 Years - 25 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • to 25 years of age
  • Willingness to provide blood samples

You may not qualify if:

  • Allergy to blueberries or any other Vaccinium species
  • Diagnosis or symptoms of anxiety, depression, or other mental health conditions
  • Any medically significant condition (e.g. anemia, gastrointestinal disorders, diabetes)
  • Use of psychoactive medication or recreational drugs in the last two weeks
  • Current use of medication that could interact with the intervention (e.g. antibiotics)
  • Obesity or underweight
  • Participation in other interventional studies in the last month
  • Pregnancy or lactation

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

School of Psychology and Clinical Languages, University of Reading

Reading, Berkshire, RG6 6AL, United Kingdom

Location

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

May 27, 2021

First Posted

June 22, 2021

Study Start

May 26, 2021

Primary Completion

August 27, 2021

Study Completion

August 27, 2021

Last Updated

September 21, 2021

Record last verified: 2021-09

Data Sharing

IPD Sharing
Will share
Shared Documents
SAP

Locations